Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]

Promoting Self-Management in Head and Neck Cancer Survivors With Lymphedema and Fibrosis [PROMISE Trial]

The goal of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) to improve LEF self-management and reduce LEF-associated symptom burden, functional deficits, and improve quality of life in head and neck cancer (HNC) survivors.

In HNC survivors with lymphedema and fibrosis (LEF), the investigators will: 1) compare the effects of in-person LEF-SMP, telehealth LEF-SMP, and usual care on LEF severity; 2) compare the effects of in-person LEF-SMP, telehealth LEF-SMP, and usual care on LEF-related symptom burden, functional impairments, and quality of life; and 3) compare the effects of in-person LEF-SMP, telehealth LEF-SMP, and usual care on LEF-related knowledge, skills, self-efficacy, and self-care adherence.

Inclusion Criteria:

• >18 years of age
• Post HNC primary treatment
• No evidence of cancer (NED)
• Completion of initial lymphedema therapy for head and neck lymphedema
• Unable to obtain lymphedema therapy due to barriers noted above
• History of lymphedema on the face and neck, with or without fibrosis
• Ability to understand English in order to complete questionnaires
• Ability to perform self-care activities for LEF management
• Ability to provide informed consent
• Having an electronic device (a computer, tablet, iPad, or smartphone) and internet access at home
• A valid email address

Exclusion Criteria:

• Recurrent or metastatic cancer
• Any other active cancer
• Acute infection
• Acute congestive heart failure
• Acute renal failure
• Cardiac or pulmonary edema
• Sensitive carotid sinus
• Severe carotid blockage
• Uncontrolled hypertension
• Venous thrombosis
• Pregnant people
• Incarcerated patients